JP2022553060A5 - - Google Patents

Info

Publication number
JP2022553060A5
JP2022553060A5 JP2022523653A JP2022523653A JP2022553060A5 JP 2022553060 A5 JP2022553060 A5 JP 2022553060A5 JP 2022523653 A JP2022523653 A JP 2022523653A JP 2022523653 A JP2022523653 A JP 2022523653A JP 2022553060 A5 JP2022553060 A5 JP 2022553060A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022523653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553060A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029739 external-priority patent/WO2021080646A1/en
Publication of JP2022553060A publication Critical patent/JP2022553060A/ja
Publication of JP2022553060A5 publication Critical patent/JP2022553060A5/ja
Pending legal-status Critical Current

Links

JP2022523653A 2019-10-22 2020-04-24 二環式化合物及びピット・ホプキンス症候群の処置におけるそれらの使用方法 Pending JP2022553060A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962924452P 2019-10-22 2019-10-22
US62/924,452 2019-10-22
PCT/US2020/029739 WO2021080646A1 (en) 2019-10-22 2020-04-24 Bicyclic compounds and methods for their use in treating pitt hopkins syndrome

Publications (2)

Publication Number Publication Date
JP2022553060A JP2022553060A (ja) 2022-12-21
JP2022553060A5 true JP2022553060A5 (enExample) 2023-05-01

Family

ID=75620281

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523653A Pending JP2022553060A (ja) 2019-10-22 2020-04-24 二環式化合物及びピット・ホプキンス症候群の処置におけるそれらの使用方法

Country Status (13)

Country Link
US (2) US12472177B2 (enExample)
EP (1) EP4048264A4 (enExample)
JP (1) JP2022553060A (enExample)
KR (1) KR20220106123A (enExample)
CN (1) CN115243688A (enExample)
AU (1) AU2020369431B2 (enExample)
BR (1) BR112022007636A2 (enExample)
CA (1) CA3158406A1 (enExample)
CL (1) CL2022001023A1 (enExample)
CO (1) CO2022006718A2 (enExample)
IL (1) IL292408A (enExample)
WO (1) WO2021080646A1 (enExample)
ZA (1) ZA202204954B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305132A (en) * 2021-02-12 2023-10-01 Neuren Pharmaceuticals Ltd Preparations for the treatment of the Prader-Willi phenomenon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063311A2 (en) 2006-10-11 2008-05-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
SI1664050T1 (sl) 2003-09-03 2016-04-29 Neuren Pharmaceuticals Limited Nevroprotektične biciklične spojine in farmacevtski sestavki, vsebujoči le-te
WO2011037644A1 (en) * 2009-09-25 2011-03-31 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy
JP6574769B2 (ja) * 2013-07-25 2019-09-11 ニューレン ファーマシューティカルズ リミテッド 二環式化合物ならびに自閉症スペクトラム障害および神経発達障害の治療におけるそれらの使用方法

Similar Documents

Publication Publication Date Title
JP2022028828A5 (enExample)
JP2022025124A5 (enExample)
JP2021185136A5 (enExample)
JP2021169491A5 (enExample)
JP2022068302A5 (enExample)
JP2021028398A5 (enExample)
JP2023116721A5 (enExample)
JP2021038271A5 (enExample)
JP2024023385A5 (enExample)
JP2023022224A5 (enExample)
JP2021184963A5 (enExample)
JP2020042034A5 (enExample)
JP2020127428A5 (enExample)
JP2022523200A5 (enExample)
JP2024016014A5 (enExample)
JP2021518389A5 (enExample)
JP2023100643A5 (enExample)
JP2022060295A5 (enExample)
JP2025506484A5 (enExample)
JP2022537813A5 (enExample)
JP2020171301A5 (enExample)
JP2020120660A5 (enExample)
JP2021524864A5 (enExample)
JP2022022379A5 (enExample)
JP2023085551A5 (enExample)